Bruce Mayer, MD
Family Medicine · Williamsburg, VANPI 1104806173
Payments from drug & device makers
Across 412 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$605
- Lilly USA, LLC$569
- Pfizer$554
- Biohaven Pharmaceuticals, Inc.$473
- Biohaven Pharmaceutical Holding Company Ltd.$420
- plus $3K from 30 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$250
What the payments were for
- Food & beverage$6,770100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 120 | $1,631 |
| Novo Nordisk | 42 | $605 |
| Lilly USA, LLC | 39 | $569 |
| Pfizer | 33 | $554 |
| Biohaven Pharmaceuticals, Inc. | 16 | $473 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $420 |
| Boehringer Ingelheim | 22 | $394 |
| AstraZeneca | 20 | $349 |
| GSK | 22 | $347 |
| Amgen | 12 | $180 |
| Indivior Inc. | 11 | $152 |
| Kowa Pharmaceuticals America, Inc. | 7 | $133 |
| Amarin Pharma, Inc. | 7 | $123 |
| Abbott | 4 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Radius Health, Inc. | 4 | $68 |
| Genentech USA, Inc. | 4 | $67 |
| Johnson & Johnson | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Virtus Pharmaceuticals LLC | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Antares Pharma, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Tolmar, Inc. | 2 | $35 |
| Watermark Medical, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Braeburn Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Tris Pharma Inc | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$247
- QULIPTA$125
How this compares
$6,785 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $88,818 |
| OzempicSemaglutide | 32 | $37,478 |
| JardianceEmpagliflozin | 18 | $23,796 |
| JanuviaSitagliptin Phosphate | 25 | $22,342 |
| TrulicityDulaglutide | 13 | $21,669 |
| BelbucaBuprenorphine Hcl | 14 | $11,705 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 76 | $10,279 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $8,345 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $7,207 |
| Oxycodone Hcl | 263 | $7,064 |
| Repatha SureclickEvolocumab | 13 | $6,936 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 138 | $5,550 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,118 |
| Buprenorphine | 11 | $3,827 |
| Fenofibrate | 139 | $3,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $554 | $88,81866 claims |
| Novo NordiskOzempic | $605 | $37,47832 claims |
| Boehringer IngelheimJardiance | $394 | $23,79618 claims |
| Lilly USA, LLCTrulicity | $569 | $21,66913 claims |
| Indivior Inc.Suboxone | $152 | $7,20714 claims |
| AstraZenecaSymbicort | $349 | $5,11815 claims |
| AbbVieSynthroid | $1,631 | $2,04431 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $1,245137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Williamsburg
- Monique SesslerWilliamsburg$22K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.